⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMY News
Bristol-Myers Squibb Co.
Zapata Quantum Adds Financial Veteran William Klitgaard to Board as Company Aims to Relist on National Exchange
globenewswire.com
ZPTA
XLNX
SYNH
AVST
CERT
BCRA
LHCG
AMZN
GOOG
MSFT
IBM
ORCL
MRK
DGX
ANTM
UNH
AMGN
GILD
BMY
PFE
ABBV
LRCX
KLAC
ADI
NXPI
QCOM
INTC
AMD
NVDA
MU
SMCI
CRWD
PANW
ZS
SNOW
DDOG
FTNT
TEAM
CRM
NOW
ADBE
INTU
PAYX
ADP
CTAS
WBA
CVS
CI
CNC
ELV
REGN
VRTX
BIIB
ALXN
AZN
NVS
ROG
SNY
XRAY
SYK
BSX
TMO
ILMN
EXAS
MDLZ
KHC
PEP
KO
MCD
SBUX
YUM
CMG
QSR
DNKN
LVS
WYNN
MGM
LULU
NKE
UA
ADDYY
PVH
RL
GPS
TJX
ROST
BBY
HD
LOW
SPG
PLD
AMT
EQIX
CCI
SBAC
PLTR
AI
UPST
SOFI
COIN
PYPL
SQ
AXP
V
MA
JPM
BAC
WFC
GS
MS
SCHW
ETFC
RJF
LPLA
BEN
IVZ
ABR
O
PSA
GOOGL
Immunoassay Market Research, Strategies, Trends and Forecasts Report 2025 with Executive Guides and Impact of Artificial Intelligence - ResearchAndMarkets.com
businesswire.com
ALGN
AMZN
BDX
BIO
BMY
CDNS
CERN
CHKP
CLVS
CODX
CRSP
CYTK
DELL
DGX
DHR
DIS
DTC
DXCM
ENZ
EXAS
FSLR
GILD
GOOG
IDXX
ILMN
INCY
INTC
ISRG
JNJ
LULU
LUMX
MDLZ
MRNA
MSFT
MYL
NBIX
NCLH
NFLX
NVS
NVTA
ORCL
ORGO
OSIP
OTIS
PANW
PFE
PG
PGR
PPC
PRGO
QCOM
QGEN
QORV
QUID
REGN
ROCH
ROST
SGEN
SIRI
SNPS
SPLK
SRPT
SWKS
SYK
TCOM
TEAM
TEVA
TGT
TMO
TSLA
TXN
ULTA
UNH
VRTX
WBA
WDC
WEC
WFC
XRAY
XTRA
ZBRA
Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors to Support Portfolio Progression into Heart Failure
prnewswire.com
PFE
NVS
BMY
ABBV
Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
prnewswire.com
GILD
ABBV
MRK
BMY
Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman
businesswire.com
BMY
CMRT
VIR
AI Proteins Raises $41.5M Series A Financing to Advance De Novo Miniproteins as a New Therapeutic Modality
businesswire.com
BMY
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
businesswire.com
BMY
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
businesswire.com
BMY
Update on Phase 3 Librexia ACS Trial
businesswire.com
BMY
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
businesswire.com
BMY